Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 16:01 ET | Source: Memento Medicines, Inc.

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF, in development for neovascular...